Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Net revenue	$ 15,856,539	$ 15,559,439
Drug Product
Disaggregation of Revenue [Line Items]
Net revenue	255,000	68,000
Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	15,602,000	15,491,000
United States
Disaggregation of Revenue [Line Items]
Net revenue	14,195,000	13,418,000
United States | Drug Product
Disaggregation of Revenue [Line Items]
Net revenue	199,000	0
United States | Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	13,996,000	13,418,000
Rest of World
Disaggregation of Revenue [Line Items]
Net revenue	1,662,000	2,141,000
Rest of World | Drug Product
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net revenue	1,606,000	2,073,000
Point-in-time | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	199,000
Point-in-time | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	15,112,000	14,996,000
Point-in-time | United States | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	199,000
Point-in-time | United States | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	13,506,000	12,923,000
Point-in-time | Rest of World | Drug Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	0
Point-in-time | Rest of World | Concentrate Product Sales
Disaggregation of Revenue [Line Items]
Net revenue	1,606,000	2,073,000
Over time | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000
Over time | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	490,000	495,000
Over time | United States | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	0	0
Over time | United States | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	490,000	495,000
Over time | Rest of World | Drug License Fee
Disaggregation of Revenue [Line Items]
Net revenue	56,000	68,000
Over time | Rest of World | Concentrate Product License Fee
Disaggregation of Revenue [Line Items]
Net revenue	$ 0	$ 0